Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

JBH 492

Next Previous
Drug Profile

JBH 492

Alternative Names: Anti-CCR7 antibody-drug conjugate - Novartis Pharmaceuticals; JBH-492

Latest Information Update: 15 Nov 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis Pharmaceuticals
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Maytansinoids
  • Mechanism of Action Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma

Most Recent Events

  • 05 Sep 2024 Novartis Pharmaceuticals terminates a phase I clinical trials in Non-Hodgkin's lymphoma and Chronic lymphocytic leukaemia in Japan, Spain, Singapore, South Korea, Finland, Israel and Germany due to business, strategic, and development considerations and not due to any safety concerns (Parenteral) (NCT04240704)
  • 05 Apr 2024 JBH 492 is still in phase I trials for Non-Hodgkin's lymphoma in Japan
  • 05 Apr 2024 Pharmacodynamics, pharmacokinetics and adverse events data from a phase I trial in Chronic lymphocytic leukaemia and Non-Hodgkin's lymphoma presented at 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top